Randomized trial shows BAY 94-8862 decreases biomarkers in chronic heart failure and kidney disease, suggesting it may be safer than existing treatments.
In patients with HFrEF and moderate CKD, BAY 94-8862 5-10 mg/day was at least as effective as spironolactone 25 or 50 mg/day in decreasing biomarkers of haemodynamic stress, but it was associated with lower incidences of hyperkalaemia and WRF.
No takes yet. Share an insight, caveat, or question.
Pitt et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: